Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Medical hypotheses"
DOI: 10.1016/j.mehy.2018.05.005
Abstract: Immune checkpoint inhibitors have profoundly altered the therapeutic landscape of several malignancies. The establishment of predictive biomarkers for checkpoint blockades is of the considerable importance in the identification of populations likely to experience a good… read more here.
Keywords: clinical benefit; immunotherapy; tumor mutation; burden ... See more keywords
Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer
Sign Up to like & getrecommendations! Published in 2021 at "Bioscience Reports"
DOI: 10.1042/bsr20203336
Abstract: Abstract Tumor mutation burden (TMB) was a promising marker for immunotherapy. We aimed to investigate the prognostic role of TMB and its relationship with immune cells infiltration in gastric cancer (GC). We analyzed the mutation… read more here.
Keywords: infiltration; mutation burden; gastric cancer; tumor mutation ... See more keywords
Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report
Sign Up to like & getrecommendations! Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13070
Abstract: SMARCA4 is a subunit of the switch/sucrose non‐fermentable (SWI/SNF) chromatin‐remodeling complex. An effective treatment for SMARCA4‐deficient non‐small cell lung carcinoma (NSCLC) has not yet been established. Correlations between a response to immune checkpoint inhibitors and… read more here.
Keywords: tumor mutation; treatment; smarca4 deficient; high tumor ... See more keywords
Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT‐based radiomics signature
Sign Up to like & getrecommendations! Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13163
Abstract: Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non‐invasively predict the… read more here.
Keywords: radiomics signature; tumor mutation; driver mutations; stage lung ... See more keywords
Construction and Evaluation of a Tumor Mutation Burden-Related Prognostic Signature for Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Computational and Mathematical Methods in Medicine"
DOI: 10.1155/2021/1435827
Abstract: Thyroid carcinoma is a type of prevalent cancer. Its prognostic evaluation depends on clinicopathological features. However, such conventional methods are deficient. Based on mRNA, single nucleotide variants (SNV), and clinical information of thyroid carcinoma from… read more here.
Keywords: prognostic signature; thyroid carcinoma; tumor mutation; signature ... See more keywords
Integrative Modeling of Multiomics Data for Predicting Tumor Mutation Burden in Patients with Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "BioMed Research International"
DOI: 10.1155/2022/2698190
Abstract: Immunotherapy has been widely used in the treatment of lung cancer, and one of the most effective biomarkers for the prognosis of immunotherapy currently is tumor mutation burden (TMB). Although whole-exome sequencing (WES) could be… read more here.
Keywords: lung cancer; tumor mutation; mutation burden; model ... See more keywords
Plasma Tumor Mutation Burden and Response to Pembrolizumab—Letter
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0903
Abstract: Predictive biomarkers are critical for patient selection in immune checkpoint inhibitor (ICI) therapy. However, the term “predictive” are often confused with “prognostic,” leading to inappropriate treatment choice in clinical practice and research. We read with… read more here.
Keywords: burden response; tumor mutation; mutation burden; pembrolizumab letter ... See more keywords
Plasma Tumor Mutation Burden and Response to Pembrolizumab—Response
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-1073
Abstract: We have carefully reviewed the letter from Li and colleagues and believe that there were misunderstandings of the results and interpretation of the findings, which we would like to take the opportunity to clarify. We… read more here.
Keywords: burden response; response; tumor mutation; mutation burden ... See more keywords
Abstract 2771: Correlation of tumor mutation burden and chemotherapy outcomes in colorectal cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-2771
Abstract: Background: The Cancer Genome Atlas (TCGA) has identified 16% of colorectal cancers (CRC) to have defects in mechanisms that repair spontaneous DNA damage, and consequently have high tumor mutation burden (TMB). Although, there is accumulating… read more here.
Keywords: chemotherapy; tmb; tumor mutation; cancer ... See more keywords
Abstract 3614: Evaluation of a commercial targeted NGS panel for tumor mutation burden assessment in FFPE tissue
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-3614
Abstract: Checkpoint inhibitors have been approved for the treatment of solid tumor and hematological malignancies. While significant responses have been observed in a subset of patients, outcomes are variable and there is a need to identify… read more here.
Keywords: panel; tumor mutation; tmb; mutation burden ... See more keywords
Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Cell International"
DOI: 10.1186/s12935-021-01774-6
Abstract: Background UCEC is the most common gynecological malignancy in many countries, and its mechanism of occurrence and development is related to tumor mutation burden (TMB) and immune cell infiltration. Therefore, it is necessary to systematically… read more here.
Keywords: immune; immune cell; tumor mutation; mutation burden ... See more keywords